Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: JAZZ

Jazz Pharmaceuticals plc

Healthcare | Biotechnology

No licensed closing price on file for JAZZ. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$14.63

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 06:02 UTC.

What Jazz Pharmaceuticals plc does

Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing medicines for rare diseases with limited treatment options. The company markets several approved therapies across epilepsies, cancers, and sleep disorders, including Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for seizure disorders, and cancer treatments such as Ziihera, Modeyso, and Zepzelca. The company operates through a strategy centered on strong commercial execution, pipeline advancement, efficient development capabilities, and strategic acquisitions to complement its existing portfolio.

Summarized from Jazz Pharmaceuticals plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$14.63
Return on equity-8.25%
Debt/equity0.91

Revenue, margins & earnings

FY2021: net loss $330M on revenue $3.09B$3.09BFY2021FY2022: net loss $224M on revenue $3.66B$3.66BFY2022FY2023 Net income: $415MFY2023 Taxes & interest: $164MFY2023 Operating costs: $3.26B$3.83BFY2023FY2024 Net income: $560MFY2024 Taxes & interest: $157MFY2024 Operating costs: $3.35B$4.07BFY2024FY2025: net loss $356M on revenue $4.27B$4.27BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-07
  • 2026-10-07President & CEOSale-2,000$472.8K
  • 2026-10-05DirectorSale-6,000$1.38M
  • 2026-09-14EVP & Chief Legal OfficerSale-1,200$289.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Jazz Pharmaceuticals plc do?

Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing medicines for rare diseases with limited treatment options.

When did JAZZ last file with the SEC?

Jazz Pharmaceuticals plc's most recent SEC filing on record is a DEF 14A filed 2026-06-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:02 UTC. This page is also available as JSON at /api/data?ticker=JAZZ and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for JAZZ and 5,000+ tickers.

Create a free account — keep JAZZ
For your agent
GET /api/data?ticker=JAZZ

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt